Xiangyi Jiang

901 total citations
43 papers, 729 citations indexed

About

Xiangyi Jiang is a scholar working on Infectious Diseases, Virology and Organic Chemistry. According to data from OpenAlex, Xiangyi Jiang has authored 43 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 30 papers in Virology and 14 papers in Organic Chemistry. Recurrent topics in Xiangyi Jiang's work include HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (30 papers) and Click Chemistry and Applications (10 papers). Xiangyi Jiang is often cited by papers focused on HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (30 papers) and Click Chemistry and Applications (10 papers). Xiangyi Jiang collaborates with scholars based in China, Belgium and United States. Xiangyi Jiang's co-authors include Xinyong Liu, Peng Zhan, Dongwei Kang, Lanlan Jing, Gaochan Wu, Erik De Clercq, Christophe Pannecouque, Xia Hao, Waleed A. Zalloum and Zhao Wang and has published in prestigious journals such as Journal of Medicinal Chemistry, Molecules and RSC Advances.

In The Last Decade

Xiangyi Jiang

40 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiangyi Jiang China	14	345	322	275	274	167	43	729
Lanlan Jing China	13	258 0.7×	325 1.0×	221 0.8×	206 0.8×	103 0.6×	22	623
Tim H. M. Jonckers Belgium	17	334 1.0×	412 1.3×	383 1.4×	197 0.7×	194 1.2×	32	981
Jayakanth Kankanala United States	19	302 0.9×	303 0.9×	365 1.3×	244 0.9×	191 1.1×	30	863
Charles A. Flentge United States	9	445 1.3×	233 0.7×	212 0.8×	303 1.1×	101 0.6×	14	738
Sanjeev Kumar V. Vernekar United States	13	246 0.7×	271 0.8×	235 0.9×	181 0.7×	53 0.3×	16	577
Dominique Surleraux United States	12	588 1.7×	214 0.7×	205 0.7×	425 1.6×	189 1.1×	23	858
Cristina Gardelli Italy	14	239 0.7×	287 0.9×	202 0.7×	125 0.5×	84 0.5×	26	584
Christopher T. Lemke Canada	15	287 0.8×	112 0.3×	291 1.1×	276 1.0×	58 0.3×	27	647
Vandna Munshi United States	13	357 1.0×	227 0.7×	208 0.8×	278 1.0×	105 0.6×	14	592
Joan A. Zugay United States	10	499 1.4×	320 1.0×	289 1.1×	399 1.5×	66 0.4×	18	812

Countries citing papers authored by Xiangyi Jiang

Since Specialization

Citations

This map shows the geographic impact of Xiangyi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangyi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangyi Jiang more than expected).

Fields of papers citing papers by Xiangyi Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangyi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangyi Jiang. The network helps show where Xiangyi Jiang may publish in the future.

Co-authorship network of co-authors of Xiangyi Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangyi Jiang. A scholar is included among the top collaborators of Xiangyi Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangyi Jiang. Xiangyi Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Xiangyi, Heng Gao, Zhen Gao, et al.. (2025). Structure- and Privileged Fragment-Based Iterative Optimization: Discovery of 2,4-Disubstituted-6-aminopyrimidines as Novel HIV-1 NNRTIs with Potent Activity against Drug-Resistant Strains and Favorable Safety Profiles. Journal of Medicinal Chemistry. 68(21). 23345–23362.

Xu, Shujing, Lin Sun, Prem P. Sharma, et al.. (2025). Design, synthesis and structure-activity relationships of novel HIV capsid inhibitors with potent antiviral activities. European Journal of Medicinal Chemistry. 295. 117784–117784.

Jing, Lanlan, Gaochan Wu, Fabao Zhao, et al.. (2024). Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization. European Journal of Medicinal Chemistry. 277. 116772–116772. 4 indexed citations

Jiang, Xiangyi, et al.. (2024). Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities. Drug Discovery Today. 29(8). 104074–104074. 8 indexed citations

Jiang, Xiangyi, Waleed A. Zalloum, Zhen Gao, et al.. (2024). Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses. European Journal of Medicinal Chemistry. 280. 116941–116941. 2 indexed citations

Jiang, Xiangyi, Heng Gao, Boshi Huang, et al.. (2024). Discovery of novel fused-heterocycle-bearing diarypyrimidine derivatives as HIV-1 potent NNRTIs targeting tolerant region I for enhanced antiviral activity and resistance profile. European Journal of Medicinal Chemistry. 281. 117033–117033. 2 indexed citations

Xu, Shujing, Lin Sun, Michael J. Barnett, et al.. (2023). Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators. Journal of Medicinal Chemistry. 66(23). 16303–16329. 7 indexed citations

Jiang, Xiangyi, Boshi Huang, Waleed A. Zalloum, et al.. (2023). Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles. European Journal of Medicinal Chemistry. 258. 115605–115605. 7 indexed citations

Zhang, Xujie, Lin Sun, Shujing Xu, et al.. (2023). Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators. RSC Medicinal Chemistry. 14(7). 1272–1295. 3 indexed citations

10.

Sharma, Prem P., Xiangyi Jiang, Brijesh Rathi, et al.. (2022). Design, Synthesis and Structure—Activity Relationships of Phenylalanine-Containing Peptidomimetics as Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction. Molecules. 27(18). 5995–5995. 2 indexed citations

11.

Xu, Shujing, Lin Sun, Waleed A. Zalloum, et al.. (2022). Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators. Molecules. 27(23). 8415–8415. 4 indexed citations

12.

Kang, Dongwei, Yanying Sun, Da Feng, et al.. (2022). Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Journal of Medicinal Chemistry. 65(3). 2458–2470. 14 indexed citations

13.

Cherukupalli, Srinivasulu, Minghui Xie, Wenbo Wang, et al.. (2022). Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry. 65(5). 3729–3757. 49 indexed citations

14.

Zhang, Xujie, Lin Sun, Shujing Xu, et al.. (2022). Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators. Molecules. 27(21). 7640–7640. 4 indexed citations

15.

Huang, Boshi, Tiziana Ginex, F. Javier Luque, et al.. (2021). Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry. 64(18). 13604–13621. 13 indexed citations

16.

Zhang, Xujie, Lin Sun, Megan E. Meuser, et al.. (2021). Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry. 226. 113848–113848. 15 indexed citations

17.

Wang, Zhao, Waleed A. Zalloum, Wenbo Wang, et al.. (2021). Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. Journal of Medicinal Chemistry. 64(18). 13658–13675. 20 indexed citations

18.

Xu, Shujing, Lin Sun, Alexej Dick, et al.. (2021). Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry. 227. 113903–113903. 22 indexed citations

19.

Kang, Dongwei, Yanying Sun, N. Arul Murugan, et al.. (2020). Structure–Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ACS Infectious Diseases. 6(8). 2225–2234. 13 indexed citations

20.

Jiang, Xiangyi, Gaochan Wu, Waleed A. Zalloum, et al.. (2019). Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. RSC Advances. 9(50). 28961–28986. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact